Category: Cardiogenic Shock


Managing Shock at the “Battlefront” of Surgery

Key Takeaways

  • Dr. Alexander Truesdell of the INOVA Heart and Vascular Institute discusses how physicians can apply the same shock management principles found on the battlefront into everyday surgical practice.
  • Early recognition of shock and early revascularization are two essential elements of successful treatment for shock on the battlefield as well as in conventional care centers.
For the past few decades, early revascularization has been considered the cornerstone of treatment for cardiogenic shock (CS). Despite widespread adoption and implementation of this management strategy, rates of mortality following interventional cardiology procedures for CS remain high.Dr. Alexander Truesdell of the INOVA Heart and Vascular Institute mentions in his editorial War on Shock that the method for treating CS requires a more aggressive, combat-like approach, embracing strategies he learned while serving as an interventional cardiologist in Iraq and Afghanistan.1 “Only with strong leadership, teamwork, and a national commitment to a joint integrated countrywide network of cardiogenic shock care, research, and innovation,” said Truesdell, “can we hope to achieve our desired goal of zero preventable death from cardiogenic shock.” Continue readingManaging Shock at the “Battlefront” of Surgery

The Association Between Obesity and In-Hospital Mortality in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction

Key Takeaways

  • Obesity is paradoxically associated with favorable mortality outcomes in acute myocardial infarction (AMI).
  • Association between obesity and in-hospital mortality among patients with cardiogenic shock (CS) complicating AMI (N=290,894) was retrospectively studied.
  • Obese patients had lower in-hospital mortality compared with nonobese patients (28.2% vs 36.5%, respectively), but key baseline differences in the obese group may explain this association.
More than one-third of the adult population in the United States (35.7%) are considered clinically obese.1 The increasing prevalence of obesity has become difficult to ignore as research continues to support the association of obesity--defined as a body mass index of 30 or greater--with poor cardiovascular health.Despite obesity having a direct link to known cardiovascular risk factors, including diabetes, hypertension, and hypercholesterolemia, previous research has shown a paradoxical protective association between obesity and established cardiovascular disease.2 This “obesity paradox” states that patients with obesity may have better outcomes following a cardiovascular event when compared with nonobese patients. Continue readingThe Association Between Obesity and In-Hospital Mortality in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction

Developing a Cardiogenic Shock Protocol and a Heart Team Approach with Dr. Salvatore Mannino

Dr. Sal Mannino and a multi-disciplinary team successfully implemented a cardiogenic shock algorithm at a very busy tertiary center, to move away from unilateral decision-making and to serve as a guide for physicians, nurses, and other healthcare providers. He shares the successes and challenges of creating an algorithm as well as how to best disseminate … Continue reading “Developing a Cardiogenic Shock Protocol and a Heart Team Approach with Dr. Salvatore Mannino”

Detroit Cardiogenic Shock Initiative: Initial Results

Data presented by Dr. William O’Neill of Henry Ford Hospital System at the 66th Annual Scientific Session of the American College of Cardiology also included new data from the Detroit Cardiogenic Shock Initiative (DCSI), an unprecedented collaboration between five heart hospitals in Detroit, with the goal of determining whether outcomes in cardiogenic shock can be … Continue reading “Detroit Cardiogenic Shock Initiative: Initial Results”

Impella® Quality Assurance Program: Importance of Treatment Protocols to Improve Patient Survival and Heart Recovery

  Data from Abiomed’s Impella® Quality (IQ) Assurance Program, which includes the IQ Database and cVAD Registry, was presented today as late-breaking Featured Clinical Research by Dr. William O’Neill of Henry Ford Hospital System at the American College of Cardiology (ACC) 66th Annual Scientific Session in Washington, D.C. These data were derived from the IQ Database … Continue reading “Impella® Quality Assurance Program: Importance of Treatment Protocols to Improve Patient Survival and Heart Recovery”

Detroit CSI: Collaboration to Improve Outcomes in Cardiogenic Shock

Announced Wednesday, the Detroit Cardiogenic Shock Initiative (CSI) is an innovative collaboration between five hospital systems in metro Detroit with the goal of determining whether outcomes in cardiogenic shock can be improved by using Impella® as early as possible for patients in the shock spiral. View the Full Story Here Led by Dr. Bill O’Neill … Continue reading “Detroit CSI: Collaboration to Improve Outcomes in Cardiogenic Shock”

Cardiogenic Shock Clinical Dossier

Impella 2.5®, Impella CP®, Impella 5.0®, and Impella LD® heart pumps are now  FDA indicated to provide treatment of ongoing cardiogenic shock. In this setting, the Impella® heart pumps have the ability to stabilize the patient’s hemodynamics, unload the left ventricle, perfuse the end organs, and allow for recovery of the native heart.

Top Cardiogenic Shock Treatment Objectives and Device Options

In patients with acute myocardial infarction (AMI), cardiogenic shock (CS) is a primary cause of mortality. According to ACC.org’s “Latest in Cardiology”, AMI with CS presents three main treatment objectives, all of which can be achieved with acute mechanical circulatory support devices:  Achieve a mean arterial pressure and vital organ perfusion,  Reduce myocardial oxygen demand … Continue reading “Top Cardiogenic Shock Treatment Objectives and Device Options”